Encompass Health Corporation (EHC) saw its stock price soar 5.22% on Friday in the pre-market trading session, outperforming the broader market. This surge can be attributed to positive analyst commentary following the company's recent quarterly earnings report.
Barclays raised its price target on EHC to $118 from $116 while maintaining an Overweight rating on the shares. The analysts cited the company's strong Q4 performance as the driving factor behind their increased price target.
Additionally, Truist Financial's David S. Macdonald reiterated a Buy rating on Encompass Health, expressing confidence in the company's growth prospects. Macdonald's report highlighted the company's solid financials and positive outlook.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。